Search

Your search keyword '"Fartoux L"' showing total 150 results
Start Over Author "Fartoux L"
150 results on '"Fartoux L"'

7. SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

Author

Vogel, A., primary, Edeline, J., additional, Ogasawara, S., additional, Kudo, M., additional, Finn, R., additional, Palmer, D., additional, Verslype, C., additional, Zagonel, V., additional, Fartoux, L., additional, Sarker, D., additional, Verset, G., additional, Chan, S., additional, Knox, J., additional, Cheng, A., additional, Daniele, B., additional, Yau, T., additional, Wang, A., additional, Hatogai, K., additional, Siegel, A., additional, and Cattan, S., additional

Published
2022
Full Text
View/download PDF

8. Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study

Author

Brustia, R, Langella, S, Kawai, T, Fonseca, G, Schielke, A, Colli, F, Resende, V, Fleres, F, Roulin, D, Leyman, P, Giacomoni, A, Granger, B, Fartoux, L, De Carlis, L, Demartines, N, Sommacale, D, Sanches, M, Patrono, D, Detry, O, Herman, P, Okumura, S, Ferrero, A, Scatton, O, Uemoto, S, Perdigao, F, Nolasco, F, Laroche, S, Romagnoli, R, Famularo, S, Brustia R., Langella S., Kawai T., Fonseca G. M., Schielke A., Colli F., Resende V., Fleres F., Roulin D., Leyman P., Giacomoni A., Granger B., Fartoux L., De Carlis L., Demartines N., Sommacale D., Sanches M. D., Patrono D., Detry O., Herman P., Okumura S., Ferrero A., Scatton O., Uemoto S., Perdigao F., Nolasco F., Laroche S., Romagnoli R., Famularo S., Brustia, R, Langella, S, Kawai, T, Fonseca, G, Schielke, A, Colli, F, Resende, V, Fleres, F, Roulin, D, Leyman, P, Giacomoni, A, Granger, B, Fartoux, L, De Carlis, L, Demartines, N, Sommacale, D, Sanches, M, Patrono, D, Detry, O, Herman, P, Okumura, S, Ferrero, A, Scatton, O, Uemoto, S, Perdigao, F, Nolasco, F, Laroche, S, Romagnoli, R, Famularo, S, Brustia R., Langella S., Kawai T., Fonseca G. M., Schielke A., Colli F., Resende V., Fleres F., Roulin D., Leyman P., Giacomoni A., Granger B., Fartoux L., De Carlis L., Demartines N., Sommacale D., Sanches M. D., Patrono D., Detry O., Herman P., Okumura S., Ferrero A., Scatton O., Uemoto S., Perdigao F., Nolasco F., Laroche S., Romagnoli R., and Famularo S.

Abstract

Purpose: A preoperative risk score (PRS) to predict outcome of patients with intrahepatic cholangiocarcinoma treated by liver surgery could be clinically relevant.To assess accuracy for broadly adoption, external validation of predictive models on independent datasets is crucial. The objective of this study was to externally validate the score for prediction of long-term outcomes after liver surgery for intrahepatic cholangiocarcinoma proposed by Sasaki et al. and based on preoperative albumin, neutrophil-to-lymphocytes-ratio, CA19-9 and tumor size. Methods: Patients treated by liver surgery for intrahepatic cholangiocarcinoma at 11 international HPB centers from 2001 to 2018 were included in the external validation cohort. Harrell's c-index and Hosmer-Lemeshow analyses were used to test PRS discrimination and calibration. Kaplan–Meier curve for risk groups as described in the original study were displayed. Results: A total of 355 patients with 174 deaths during the follow-up period (median = 41.7 months, IQR 32.8–50.6) were included. The median PRS value was 14.7 (IQR 10.7–20.6), with normal distribution across the cohort. A Cox regression on PRS covariates found coefficients similar to those of the derivation cohort, except for tumor size. Measures of discrimination estimated by Harrell's c-index was 0.61(95%CI:0.56–0.67) and Hosmer-Lemeshow p = 0.175. The Kaplan-Meyer estimation showed reasonable discrimination across risk groups, with 5years survival rate ranging from 20.1% to 0%. Conclusion: In this external validation cohort, the PRS had mild discrimination and poor calibration performance, similarly to the original publication. Nevertheless, its ability to identify different classes of risk is clinically useful, for a better tailoring of a therapeutic strategy.

Published
2020

14. Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study

Author

Brustia, R., primary, Langella, S., additional, Kawai, T., additional, Fonseca, G Marques, additional, Schielke, A., additional, Fartoux, L., additional, Colli, F., additional, Fleres, F., additional, Famularo, S., additional, Giacomoni, A., additional, Sommacale, D., additional, Patrono, D., additional, Detry, O., additional, Hermann, P., additional, Okumura, S., additional, and Scatton, O., additional

Published
2020
Full Text
View/download PDF

16. Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer

Author

Poynard, T., primary, Peta, V., additional, Munteanu, M., additional, Moussalli, J., additional, Rudler, M., additional, Lebray, P., additional, Massard, J., additional, Pais, R., additional, Bonyhay, L., additional, Charlotte, F., additional, Thibault, V., additional, Lucidarme, O., additional, Eyraud, D., additional, Savier, E., additional, Scatton, O., additional, Valantin, M.A., additional, Ngo, Y., additional, Ngo, A., additional, Drane, F., additional, Bismut, F., additional, Fartoux, L., additional, Deckmyn, O., additional, Cacoub, P., additional, Rosmorduc, O., additional, Housset, C., additional, Thabut, D., additional, and Ratziu, V., additional

Published
2018
Full Text
View/download PDF

17. Health-Related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)

Author

Vogel, A, primary, Qin, S, additional, Kudo, M, additional, Hudgens, S, additional, Yamashita, T, additional, Yoon, J, additional, Fartoux, L, additional, Simon, K, additional, Lopez, C, additional, Sung, M, additional, Dutcus, C, additional, Kraljevic, S, additional, Tamai, T, additional, Grunow, N, additional, Meier, G, additional, and Breder, V, additional

Published
2017
Full Text
View/download PDF

18. Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Author

Edeline, J., primary, Bonnetain, F., additional, Phelip, J-M., additional, Watelet, J., additional, Hammel, P., additional, Joly, J-P., additional, Benabdelghani, M., additional, Fartoux, L., additional, Bouhier-Leporrier, K., additional, Jouve, J-L., additional, Faroux, R., additional, Guerin-Meyer, V., additional, Assenat, E., additional, Seitz, J-F., additional, Malka, D., additional, Louvet, C., additional, Bertaut, A., additional, Juzyna, B., additional, Stanbury, T., additional, and Boucher, E., additional

Published
2017
Full Text
View/download PDF

19. Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)

Author

Vogel, A., primary, Qin, S., additional, Kudo, M., additional, Hudgens, S., additional, Yamashita, T., additional, Yoon, J-H., additional, Fartoux, L., additional, Simon, K., additional, López López, C., additional, Sung, M., additional, Dutcus, C., additional, Kraljevic, S., additional, Tamai, T., additional, Grunow, N., additional, Meier, G., additional, and Breder, V., additional

Published
2017
Full Text
View/download PDF

24. FRI-128 - Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer

Author

Poynard, T., Peta, V., Munteanu, M., Moussalli, J., Rudler, M., Lebray, P., Massard, J., Pais, R., Bonyhay, L., Charlotte, F., Thibault, V., Lucidarme, O., Eyraud, D., Savier, E., Scatton, O., Valantin, M.A., Ngo, Y., Ngo, A., Drane, F., Bismut, F., Fartoux, L., Deckmyn, O., Cacoub, P., Rosmorduc, O., Housset, C., Thabut, D., and Ratziu, V.

Published
2018
Full Text
View/download PDF

25. 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC

Author

Neuzillet, C., primary, Seitz, J.F., additional, Fartoux, L., additional, Malka, D., additional, Lledo, G., additional, Tijeras-Raballand, A., additional, De Gramont, A., additional, Ronot, M., additional, Bouattour, M., additional, Dreyer, C., additional, Granier, M., additional, Benner, S., additional, Amin, A., additional, Bourget, P., additional, Hadengue, A., additional, Roldan, N., additional, Chibaudel, B., additional, Raymond, E., additional, and Faivre, S., additional

Published
2015
Full Text
View/download PDF

26. PD-005 Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma

Author

Palmer, D., primary, Meyer, T., additional, Chao, Y., additional, Deptala, A., additional, Fartoux, L., additional, Feng, Y.-H., additional, Graham, J., additional, Lin, D.-Y., additional, Ma, Y.T., additional, Peck-Radosavljevic, M., additional, Ross, P., additional, Ryoo, B.-Y., additional, Yen, C.-J., additional, Hocke, J., additional, Vlassak, S., additional, Wenz, A., additional, Loembe, A.-B., additional, and Cheng, A.-L., additional

Published
2015
Full Text
View/download PDF

27. LBA29 - Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

Author

Edeline, J., Bonnetain, F., Phelip, J-M., Watelet, J., Hammel, P., Joly, J-P., Benabdelghani, M., Fartoux, L., Bouhier-Leporrier, K., Jouve, J-L., Faroux, R., Guerin-Meyer, V., Assenat, E., Seitz, J-F., Malka, D., Louvet, C., Bertaut, A., Juzyna, B., Stanbury, T., and Boucher, E.

Published
2017
Full Text
View/download PDF

29. Second Line Therapy with Sunitinib As Single Agent in Patients with Advanced Intrahepatic Cholangiocarcinoma (Update on Sun-Ck Phase Ii Trial)

Author

Neuzillet, C., primary, Seitz, J., additional, Fartoux, L., additional, Malka, D., additional, Lledo, G., additional, Tijeras-Raballand, A., additional, De Gramont, A., additional, Ronot, M., additional, Bouattour, M., additional, Dreyer, C., additional, Amin, A., additional, Bourget, P., additional, Hadengue, A., additional, Roldan, N., additional, Chibaudel, B., additional, Raymond, E., additional, and Faivre, S., additional

Published
2014
Full Text
View/download PDF

32. 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

Author

Llovet, J.M., primary, Decaens, T., additional, Raoul, J.-L., additional, Boucher, E., additional, Kudo, M., additional, Chang, C., additional, Kang, Y.-K., additional, Assenat, E., additional, Lim, H.-Y., additional, Boige, V., additional, Mathurin, P., additional, Fartoux, L., additional, Lin, D.-Y., additional, Bruix, J., additional, Poon, R.T., additional, Sherman, M., additional, Blanc, J.-F., additional, Finn, R., additional, Tak, W.-Y., additional, Chao, Y., additional, Ezzeddine, R., additional, Liu, D., additional, Walters, I., additional, and Park, J.-W., additional

Published
2012
Full Text
View/download PDF

36. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial

Author

Malka, D., primary, Trarbach, T., additional, Fartoux, L., additional, Mendiboure, J., additional, de la Fouchardière, C., additional, Viret, F., additional, Assenat, E., additional, Boucher, E., additional, Rosmorduc, O., additional, and Greten, T., additional

Published
2009
Full Text
View/download PDF

41. Association between IL28B polymorphism, TNF α and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance.

Author

Lemoine, M., Chevaliez, S., Bastard, J. P., Fartoux, L., Chazouillères, O., Capeau, J., Pawlotsky, J. M., and Serfaty, L.

Subjects
CHRONIC hepatitis C, INTERLEUKINS, INSULIN resistance, TUMOR necrosis factors, BIOMARKERS, GENETIC polymorphisms
Abstract

TNF α has been shown to play a role in hepatitis C virus ( HCV)-induced insulin resistance ( IR). Polymorphism of the IL28B gene that encodes IFN-lambda 3 may be associated with IR through modulation of TNF α. The aim of this study was to investigate the relationship between IL28B rs12979860 genotype, the level of TNF α activation and the degree of IR in patients with chronic hepatitis C. One hundred and thirty-three nondiabetic genotype 1 HCV-infected patients with biopsy proven noncirrhotic hepatitis C were investigated for IR (using HOMA index), IL28B rs12979860 genotype and fasting circulating levels of soluble receptor 1 of TNF α (s TNFR1) and adipokines: leptin, adiponectin and IL-6. The HOMA- IR was positively correlated with serum levels of leptin ( r = 0.35, P < 0.0001) and s TNFR1 ( r = 0.35, P < 0.0001) but not with IL-6 or adiponectin. IL28B rs12979860 CC genotype was observed in 35% patients. Genotype CC and nongenotype CC patients were similar in terms of HOMA- IR (means 1.6 ± 0.9 vs 1.7 ± 1.4) and had similar circulating levels of s TNFR1 and adipokines. Independent factors associated with IR were ferritin ( OR = 1.002, P = 0.02), leptin ( OR = 1.06, P = 0.02) and s TNFR1 ( OR = 7.9, P = 0.04). This study suggests that in nondiabetic, noncirrhotic, HCV genotype 1-infected patients, there is no relationship between IL28B rs12979860 genotype and HOMA- IR or sTNFR1 level. HCV-related IR may be mediated through TNF α independent of IL28B genotype. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

48. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Author

Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O, Lewin, Maïté, Fartoux, Laetitia, Vignaud, Alexandre, Arrivé, Lionel, Menu, Yves, and Rosmorduc, Olivier

Abstract

Objective: To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment.Materials and Methods: Two target tumors were prospectively analyzed in 12 patients at baseline, 2-weeks and 2-months treatment using b values of 0, 200, 400, 800 s/mm. Repeatability error was estimated on a healthy volunteer.Results: Lesion sizes, ADC and D values did not significantly change during treatment (overall mean values, respectively, 47.8 ± 31.0 mm, 1.34 ± 0.14 × 10⁻³ mm² s and 1.18 ± 0.22 × 10⁻³ mm²/s). However, f values significantly increased in seven responder patients (+38.39% at 2-weeks, +50.94% at 2-months, P = 0.005) while they decreased in five non responder patients (-41.93% at 2-weeks, P = 0.006). Furthermore, f was inversely correlated with αFP levels (P = 0.032) and responder patients had a higher mean overall survival (OS) than non responder patients (12.29 ± 4.46 vs. 7.80 ± 4.9 months). The % variation of f relative to baseline at 2-months was correlated with OS (P = 0.038) and symptomatic time to progression (P = 0.022).Conclusion: Contrary to ADC and D, the perfusion fraction f is a valuable marker of sorafenib treatment in advanced HCC. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

49. Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study

Author

Nicolas Demartines, Laetitia Fartoux, Benjamin Granger, Shinya Okumura, Takayuki Kawai, Paulo Herman, Raffaele Brustia, Fabiano Perdigao, Damiano Patrono, Gilton Marques Fonseca, Renato Romagnoli, Olivier Detry, Simone Famularo, Luciano De Carlis, Shinji Uemoto, Serena Langella, Sophie Laroche, Astrid Schielke, Marcelo Dias Sanches, Paul Leyman, Vivian Resende, Daniele Sommacale, Olivier Scatton, Didier Roulin, Francesco Fleres, Alessandro Giacomoni, Alessandro Ferrero, Francisco Nolasco, Fabio Colli, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Chirurgie Générale, Digestive et Endocrine [CHU Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de Chirurgie Digestive / Centre de Transplantation Hépatique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Universitaire de Liège (CHU-Liège), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Brustia, R, Langella, S, Kawai, T, Fonseca, G, Schielke, A, Colli, F, Resende, V, Fleres, F, Roulin, D, Leyman, P, Giacomoni, A, Granger, B, Fartoux, L, De Carlis, L, Demartines, N, Sommacale, D, Sanches, M, Patrono, D, Detry, O, Herman, P, Okumura, S, Ferrero, A, Scatton, O, Uemoto, S, Perdigao, F, Nolasco, F, Laroche, S, Romagnoli, R, Famularo, S, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive et Transplantation Hépatique, Hôpital Archet II, Centre de Recherche Saint-Antoine (CR Saint-Antoine), and Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP]

Subjects
Male, Neutrophils, medicine.medical_treatment, Preoperative risk, Kaplan-Meier Estimate, Cholangiocarcinoma, Leukocyte Count, 0302 clinical medicine, Long-term outcomes, Intrahepatic Cholangiocarcinoma, Aged, 80 and over, General Medicine, Middle Aged, Tumor Burden, 3. Good health, External validation, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Prognostic score, Cohort, Intra-hepatic cholangiocarcinoma, Female, 030211 gastroenterology & hepatology, Adult, medicine.medical_specialty, CA-19-9 Antigen, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 03 medical and health sciences, Clinical Decision Rules, Internal medicine, Covariate, medicine, Hepatectomy, Humans, Liver surgery, Lymphocyte Count, Survival rate, Serum Albumin, Aged, Proportional Hazards Models, Proportional hazards model, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Long-term outcome, digestive system diseases, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Surgery, business
Abstract

Purpose A preoperative risk score (PRS) to predict outcome of patients with intrahepatic cholangiocarcinoma treated by liver surgery could be clinically relevant.To assess accuracy for broadly adoption, external validation of predictive models on independent datasets is crucial. The objective of this study was to externally validate the score for prediction of long-term outcomes after liver surgery for intrahepatic cholangiocarcinoma proposed by Sasaki et al. and based on preoperative albumin, neutrophil-to-lymphocytes-ratio, CA19-9 and tumor size. Methods Patients treated by liver surgery for intrahepatic cholangiocarcinoma at 11 international HPB centers from 2001 to 2018 were included in the external validation cohort. Harrell's c-index and Hosmer-Lemeshow analyses were used to test PRS discrimination and calibration. Kaplan–Meier curve for risk groups as described in the original study were displayed. Results A total of 355 patients with 174 deaths during the follow-up period (median = 41.7 months, IQR 32.8–50.6) were included. The median PRS value was 14.7 (IQR 10.7–20.6), with normal distribution across the cohort. A Cox regression on PRS covariates found coefficients similar to those of the derivation cohort, except for tumor size. Measures of discrimination estimated by Harrell's c-index was 0.61(95%CI:0.56–0.67) and Hosmer-Lemeshow p = 0.175. The Kaplan-Meyer estimation showed reasonable discrimination across risk groups, with 5years survival rate ranging from 20.1% to 0%. Conclusion In this external validation cohort, the PRS had mild discrimination and poor calibration performance, similarly to the original publication. Nevertheless, its ability to identify different classes of risk is clinically useful, for a better tailoring of a therapeutic strategy.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results